News

Temporary suspension of the EIC Accelerator short proposals submissions

Published on | 4 months ago

Programmes EIC

Please be informed that there will be a temporary suspension of the EIC Accelerator short proposals submissions to the call HORIZON-EIC-2024-ACCELERATOR-01.

A recently published update on the Funding & Tender Portal indicates that that the short proposal call HORIZON-EIC-2024-ACCELERATOR-01 will officially close on 22 October 2024, at 5:00 PM Brussels Time.

Following this closure, it will not be possible to submit applications between 22 October and 29 October  2024. The short proposal call will be replaced by the 2025 EIC Accelerator short proposal call (HORIZON-EIC-2025-ACCELERATOR-01) upon the adoption of the 2025 EIC Work Programme, which is anticipated to take place in the last week of October (29 October).

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1536 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.